[Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
Based on the results of seven ICTH-controlled PUP studies only the virus-inactivating procedures by pasteurization (60 degrees C for 10 h), tri-n-butyl-phosphate/detergent treatment, and vapor heating (60 degrees C for 10 h and 1,200 mbar) have prevented the haemophilic patients from infections with hepatitis B, C and HIV. After the disaster of the HIV infection in haemophilic patients at the beginning of the 80's the factor concentrates given today seem to be safe for virus infections during substitution therapy. To prove this high therapeutical standard there is a need for a prospective long-term pharmaco-vigilance study under the auspices of an independent body such as the Medical Advising Committee of the National Haemophilia Society or other scientific organisations.
Pollmann
H
H
Hämophilie-Zentrum der Universitäts-Kinderklinik Münster.
D016913:Blood Component Transfusion; D017848:Blood-Borne Pathogens; D002423:Cause of Death; D005164:Factor IX / Q000627:therapeutic use*; D005169:Factor VIII / Q000627:therapeutic use*; D005858:Germany / Q000453:epidemiology; D006467:Hemophilia A / Q000401:mortality / Q000628:therapy*; D002836:Hemophilia B / Q000401:mortality / Q000628:therapy*; D006801:Humans; D012307:Risk Factors; D014777:Virus Diseases / Q000401:mortality / Q000517:prevention & control* / Q000635:transmission
D005169:Factor VIII; D005164:Factor IX
Derzeitiger Stand der Virus-sicherheit von virusinaktivierten Faktor-VIII- und -IX-Konzentraten in der Hämophiliebehandlung.